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Background. Human coronavirus NL63 (HCoV-NL63) is a globally endemic pathogen causing mild and severe respiratory tract 
infections with reinfections occurring repeatedly throughout a lifetime.
Methods. Nasal samples were collected in coastal Kenya through community-based and hospital-based surveillance. HCoV-NL63 
was detected with multiplex real-time reverse transcription PCR, and positive samples were targeted for nucleotide sequencing of 
the spike (S) protein. Additionally, paired samples from 25 individuals with evidence of repeat HCoV-NL63 infection were selected 
for whole-genome virus sequencing.
Results. HCoV-NL63 was detected in 1.3% (75/5573) of child pneumonia admissions. Two HCoV-NL63 genotypes circulated 
in Kilifi between 2008 and 2014. Full genome sequences formed a monophyletic clade closely related to contemporary HCoV-NL63 
from other global locations. An unexpected pattern of repeat infections was observed with some individuals showing higher viral 
titers during their second infection. Similar patterns for 2 other endemic coronaviruses, HCoV-229E and HCoV-OC43, were 
observed. Repeat infections by HCoV-NL63 were not accompanied by detectable genotype switching.
Conclusions. In this coastal Kenya setting, HCoV-NL63 exhibited low prevalence in hospital pediatric pneumonia admissions. 
Clade persistence with low genetic diversity suggest limited immune selection, and absence of detectable clade switching in reinfec-
tions indicates initial exposure was insufficient to elicit a protective immune response.
Keywords. virus evolution; coronavirus; repeat infection.
 
Acute bacterial and viral respiratory infections are a leading cause 
of childhood morbidity and mortality globally [1–4]. Frequently 
detected viruses include respiratory syncytial virus (RSV), influ-
enza virus, parainfluenza virus, rhinovirus, human metapneumo-
virus, and human coronavirus [5–7]. Six coronavirus species are 
known to infect humans: Severe acute respiratory syndrome corona-
virus (SARS-CoV) and Middle East respiratory syndrome corona-
virus (MERS-CoV), associated with zoonosis and high mortality 
[8–11], and Human coronavirus (HCoV)-NL63, -OC43, -229E, 
and -HKU1, with higher prevalence but reduced mortality [12–15].
Human coronaviruses can infect all age groups [13, 16, 17]. 
Infections with HCoV-NL63, HCoV-OC43, and HCoV-229E can 
occur repeatedly throughout a lifetime. Descriptions of the genetic 
diversity of endemic HCoVs are limited and the factors that allow 
repeat infections by these viruses are not fully understood. Protective 
immune responses to HCoVs may be short lived or insufficient to 
block reinfection. Alternately, the virus may evolve to avoid protec-
tive immunity, with reinfection due to immune escape variants.
A better understanding of virus reinfection might reveal 
features for improving vaccines. The vaccine concept relies on 
exposure to a subacute dose of a pathogen resulting in pro-
tective immune responses [18, 19]. Although it is generally 
thought that host immune responses are protective against 
subsequent exposure to a virus, there is evidence from some 
pathogenic viruses that prior exposure and immune responses 
to a virus may actually promote greater virus infection or 
increased pathology in subsequent exposures to the virus [20]. 
For instance, antibodies were reported to enhance SARS-CoV 
cell entry [21, 22] and an animal model of SARS-CoV infection 
in African green monkeys showed increased liver pathology in 
immunized animals [23]. Antibody enhancement of flavivirus 
infection occurs in vitro [24] and there is evidence of immune 
responses to primary infections of dengue virus or feline coro-
navirus altering secondary infections [25]. For RSV, molecular 
studies have noted that previously circulating antigenic diver-
sity may influence subsequent group and genotype predomi-
nance during the epidemics and this could be responsible for 
some of the reinfections observed in populations [26].
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Respiratory virus surveillance has been carried out in Kilifi 
County, located in Coastal Kenya, with a continuous hospi-
tal-based arm and an intermittent community-based arm [5, 
27–29]. We took advantage of 2 available cohorts with collec-
tions of upper respiratory samples to generate a set of local 
HCoV-NL63 partial spike and full genome sequences. During 
the course of a household-based community study in 2010, a 
pattern of coronavirus reinfection was noted. Samples from 
these cases were selected for detailed phylogenetic analysis.
MATERIALS AND METHODS
Study Population
This study used samples from (1) a prospective child inpatient 
(IP samples) surveillance of viral etiologies of pneumonia (2008 
to 2014) at the Kilifi County Hospital (KCH) [5] and (2) a pro-
spective household surveillance study (HH samples) conducted 
in a smaller geographical area within Kilifi County [29]. Study 
details have been previously described [5, 29–31]. The hospi-
tal pneumonia etiology study has been ongoing since 2002 and 
recruits children aged 0–59 months of age with signs of severe or 
very severe pneumonia that prompt admission. The household 
study recruited 483 participants from 47 households between 
December 2009 and June 2010, collecting nasopharyngeal 
flocked swabs from each household member twice weekly irre-
spective of symptoms. For both studies, samples were initially 
screened for a panel of respiratory viruses including 3 endemic 
coronaviruses (HCoV-229E, HCoV-NL63, and HCoV-OC43) 
using real-time reverse transcription polymerase chain reaction 
(RT-PCR) [32, 33]. A sample threshold cycle (Ct) value of <35.0 
was considered positive for the target virus. The 25 pairs of 
samples for whole-genome sequencing were selected based on 
having 2 positive NL63 samples >14 days apart. For individual 
with multiple positive isolates in each period, the samples with 
the lowest Ct (highest viral load) were selected. Furthermore, 
to distinguish prolonged shedding from reinfection, pairs were 
chosen that had at least 4 NL63-negative samples in the inter-
vening period between positive samples.
The samples in this study were collected after receiving 
informed written consent from each participant if ≥18  years 
of age or through a guardian or parent if <18 years of age and 
all children assented to participate. The study protocol was 
approved by the Scientific and Ethics Review Unit of the Kenya 
Medical Research Institute (KEMRI), Nairobi, and Coventry 
Research Ethics Committee, UK.
Laboratory Methods
Viral RNA Extraction, Spike Gene Amplification, and Sequencing
Viral RNA was extracted from nasopharyngeal swab samples 
using QIAmp viral RNA mini kit (Qiagen) using the manufac-
turer’s protocol. Synthesis of cDNA from the RNA used prim-
ers targeting the S1 domain of the HCoV-NL63 spike gene 
(Supplementary Table 1 and Supplementary Figure 1) in a 1-step 
250µL RT-PCR reaction (see Supplementary Figure 1 legend for 
details). The DNA products were purified using the Min Elute 
PCR purification kit (Qiagen) and sequenced using a ABI 3130xl 
(Applied Biosystems) instrument with BigDye terminator kit 
(Qiagen), PCR primers, and an additional 6 sequencing primers 
(HCoV-NL63_SF1, HCoV-NL63_SF1_RC, HCoV-NL63_SF2, 
HCoV-NL63_SF2_RC, HCoV-NL63_SF3, HCoV-NL63_SF3_
RC; see Supplementary Table 1). Individual spike sequences were 
quality checked, trimmed, and assembled into larger sequence 
contigs using Sequencher 5.10 (Gene Codes Corporation).
Whole-Genome Sequencing
Sample Preparation and Nucleic Acid Extraction
Total nucleic acid extraction was performed using previously 
described methods [34]. Nasopharyngeal flocked swab sam-
ple raw extracts were centrifuged for 10 minutes at 10 000 × g. 
Nonprotected DNA in the supernatant was degraded with 20 
U TURBO DNase (Ambion). Nondegraded (presumably viri-
on-protected) nucleic acid was extracted followed by reverse 
transcription using nonribosomal hexamers [35]. Second-
strand DNA synthesis was with 5 U of Klenow fragment (New 
England Biolabs) and the resulting nucleic acids were purified 
using phenol/chloroform extraction and ethanol precipitation.
Library Preparation, Sequencing, and Assembly of Short Reads
Illumina libraries were prepared for each sample. Nucleic acids 
were sheared to 400–500 nt, ligated to sample-specific indices, 
and multiplexed at 80 samples per HiSeq 2500 run, generating 
2–3 million 250 nt (HiSeq) paired-end reads per sample. The 
raw reads were trimmed to remove residual sequencing adapt-
ers and filtered to retain reads with median Phred score >35 
using QUASR v7.02 [36] and assembled into contigs using de 
novo assembly with SPAdes 3.10.1 [37]. Coronavirus contigs 
were identified with ublast [38] and a Coronaviridae protein 
database. Overlapping contigs were joined into full-length 
sequences using Geneious 8.1.8 (http://www.geneious.com/) 
and ambiguities were resolved by consulting the original short 
reads. Final quality control of genomes included a comparison 
of the sequences, their open reading frames and the encoded 
proteins with reference sequences retrieved from GenBank.
Comparison Datasets, Phylogenetic, and Recombination Analysis
All HCoV-NL63 sequences deposited in the GenBank encod-
ing the S1 domain of spike gene region or the entire genome 
were collected from GenBank (accessed September 2017). 
A  summary of all sequences used in this study is presented 
in Supplementary Table  2. Alignments were prepared using 
MAFFT v7.154 [39]. Phylogenetic trees were constructed in 
MEGA v7.0.26 [40]. The appropriate evolutionary model was 
determined using IQ-TREE program. Maximum likelihood 
methods with bootstrapping (1000 iterations) were used. The 
aligned sequences were analyzed for recombination using the 
RDP4 program.
Downloaded from https://academic.oup.com/jid/article-abstract/217/11/1728/4948258
by University of Warwick user
on 17 July 2018
1730 • JID 2018:217 (1 June) • Kiyuka et al
K-mer Method of Genotype Classification
HCoV-NL63 genotype A  and B sequence sets were prepared 
from GenBank plus the Kilifi HCoV-NL63 sequences. KMC3 
[41] was used to identify all 30-nt sequences (k-mers) present in 
genotype A sequences and not in genotype B sequences and vice 
versa. Quality-controlled short read sequences from each sam-
ple were then classified as HCoV-NL63 genotype A or genotype 
B based on the read’s content of genotype A and B-specific 30-nt 
kmers using a threshold of 20 kmer per read as defining identity 
to a genotype. Results were reported as number of HCoV-NL63 
reads (or fraction) classified as each genotype.
Accession Numbers
The HCoV-NL63 spike and full genome sequences were 
deposited in GenBank with accession numbers MG356413–
MG356452 (spike sequences) and MG428699–MG428707 (full 
genome sequences).
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Figure 1. Patterns of detection of human coronavirus NL63 (HCoV-NL63) in the 2 cohorts. A, Prevalence of HCoV-NL63 by year in the inpatient surveillance study at 
Kilifi County Hospital (KCH). B, The frequency of detection of HCoV-NL63 by month in the inpatient surveillance study at KCH, 2008–2014. C, The frequency of detection of 
HCoV-NL63 by month in the household cohort surveillance study. D, Temporal patterns of HCoV-NL63 detection in the 25 community participants chosen for whole-genome 
sequencing. Each circle indicates the date of a positive sample; the size of the circle is inversely proportional to the real-time PCR threshold cycle (Ct) value (with scale 
indicating Ct to circle size is shown at the left of the panel). The grey filled circles indicate samples that yielded sequence (spike or whole genome). All positive results are 
shown here, while for sequencing only 2 samples were selected per individual for whole-genome sequencing (see text for details).
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RESULTS
Of 5573 nasal samples collected in the hospital-based study 
between February 2008 and May 2014, diagnostic real-time 
RT-PCR identified 1.3% (75/5573) as HCoV-NL63 positive. 
Across 6 years of observation, HCoV-NL63 positive samples 
varied from 0.23% (2/873) for 2008 to 2.46% (11/447) for 2013 
(Figure 1A) with most infections detected in February to July 
(Figure 1B). In the household-based community study (16 918 
samples), HCoV-NL63 was detected in 418 (2.5%) samples col-
lected from December 2009 to June 2010 (Figure 1C). Among 
household participants, repeat infections with HCoV-NL63, 
HCoV-OC43, and HCoV-229E were identified in 21%, 5.7%, 
and 4.0% of the participants, respectively (Table  1). We 
selected paired samples from 25 subjects with HCoV-NL63 
repeat infections for whole-genome sequencing, using the 
lowest Ct value sample (highest virus titer) from both first and 
second infections (Figure 1D). From 50 samples, 9 yielded full 
genomes, while 2 yielded the spike-encoding region sequences 
only, and all were second infection samples.
HCoV-NL63 positive samples from inpatient (IP) surveil-
lance were subjected to spike-specific RT-PCR and dideoxy 
sequencing, generating 29 S1 domain sequences (2196  bp). 
These sequences were combined with the S1 domain from the 
household sequences, aligned, and a phylogeny constructed 
(Figure 2A and 2B). The sequences separated into 2 genotypes, 
A  and B.  For some of the observation years, both genotypes 
were detected in circulation (eg, 2011, 2012, and 2013)  while 
in other years only a single genotype was detectable (Figure 2A 
and 2B). A  nucleotide alignment of household genomes 
showed only a few differences distributed across their length 
(Figure 2C). All household study sequences belonged to gen-
otype A. We identified the unique S1 sequences (n = 21) from 
the Kilifi IP-household set (n = 40) and combined them with 
spike sequences from other parts of the world to infer the phy-
logenetic placement of HCoV-NL63 circulating in Kilifi within 
a global context.
The global sequences (n  =  63, 54 unique) originated from 
the United States, Haiti, Thailand, China, and the Netherlands 
and were isolated between 1990 and 2016. Their phylogeny 
including the Kilifi spike sequences confirmed the segregation 
of HCoV-NL63 strains in the S1 region into 2 genotypes (A and 
B) (Figure 3A). Similar to the Kilifi sequences, subclades within 
these genotypes were evident, mostly clustering by year of iso-
lation. We assigned these subclades into lineages, A0, A1, A2, 
B0, B1, and B2. We constructed a phylogeny based on the Kilifi 
Table 1. Baseline Characteristics for the Household Study
HCoV-NL631 HCoV-OC43 HCoV-229E
Number of individual infected (%)
Single infection 163 (74.09) 215(94.30) 119 (95.97)
Second infection 46 (20.91) 13 (5.7) 5 (4.03)
Third infection 10 (4.55) … …
Fourth infection 1 (0.45) … …
Age at infection. no. (%)
0–1 y 27 (12.27) 40 (17.54) 17 (13.71)
1–4 y 32 (14.55) 38 (16.67) 23 (18.55)
5–14 y 85 (38.64) 90 (39.47) 43 (34.68)
15–39 y 60 (27.27) 54(23.68) 31 (25.00)
40 + y 16 (7.27) 6 (2.63) 10 (8.06)
Gender of participants
Female sex, no. (%) 121 (55.00) 130 (57.20)  70 (56.45)
Time to reinfection, days, median (IQR)
Interval between reinfection episodes 47.00 (25, 94) 98 (87, 105) 72 (69, 101)
Frequency of households with at least 1 case of human coronavirus 
infection, out of the total 47 surveyed (%)
33 (70.21) 44 (93.62) 30 (63.83)
Frequency of households with at least1 case of human coronavirus 
reinfection (%)
12/18 (66.67) 7/18 (38.89) 3/18 (16)
Frequency of cases with coinfections with other viruses, no. (%)
First infection 38 (79.17) 59 (96.72) 33 (89.19)
Second infection 8 (16.67) 2 (3.28) 4 (10.81)
Third infection 2 (4.17) … …
Presence of upper respiratory symptoms, no. (%)
First infection 40 (72.73) 57 (95.00) 21 (91.30)
Second infection 12 (21.82) 3 (5.00) 2 (8.70)
Third infection 2 (3.64) … …
Fourth infection 1 (1.82) … …
For each virus, positive samples were determined by polymerase chain reaction (PCR) diagnostics, see Methods section.
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Figure 2. The genetic diversity of the Kilifi human coronavirus NL63 (HCoV-NL63) isolates. A, A maximum likelihood phylogeny of all sequenced Kilifi HCoV-NL63 strains 
derived from the S1 encoding region of the spike protein. The 2 main identified genotypes (A and B) are shown. The different circle colors preceding the taxon names on 
the phylogenetic tree depict the different years in which the samples were collected. B, Hiliter alignment of the Kilifi spike sequences. Changes between strains within the 
individual genotypes in the alignment panels are shown as colored vertical bars (orange, change to A; crimson, change to T; indigo, change to G; slateblue, change to C). C, 
A nucleotide alignment plot showing changes in the Kilifi household genomes across their length (color change coding as in B).
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(household) and global whole-genome sequences (Figure 3B). 
The household genomes formed a single monophyletic group 
within the global phylogeny (Figure 3B). The temporal occur-
rence of the 6 lineages based on the spike sequences is shown 
in Figure 3C.
Global and Kilifi spike sequences were aligned and compared 
to the HCoV-NL63 reference strain (NC_005831) to reveal 
the spike amino acid differences (Figure  4A). These patterns 
further supported the conclusion that 2 major genotypes of 
HCoV-NL63 (A and B) circulated in Kilifi over the observation 
period (4 years for clade A, May 2010 to May 2014; 5 years for 
Clade B, March 2008 to June 2013).
The binding domain for the cellular receptor for HCoV-NL63 
(ACE2) resides in the central portion of the spike protein, res-
idues 476–616 [42, 43], identified by the orange horizontal 
band marked RBD in Figure 4A top panel. Differences in this 
region were marked in Figure 4A with several amino acid poly-
morphisms persisting in multiple samples (eg, I507L, E471D, 
E572A), suggesting genetic drift or possible positive advantage 
for these residues.
Patterns of Coronavirus Repeat Infections
With both spike and full genome sequencing, full genome or 
segment sequences were successfully obtained exclusively from 
repeat infection samples. We examined this phenomenon in 
more detail.
Comparing the median Ct viral load value for first and second 
infections showed a large difference in the median Ct values, 
with second infections displaying lower Ct (higher viral loads) 
(Figure 4B). The difference between the 2 groups is greater than 
expected by chance (2-tailed P value = .0188) with the second 
exposure to the virus showing higher levels of virus replication 
than the previous exposure. When the yield of HCoV-NL63 
genome in the second infections was plotted as a function of 
the time between the first and second infection, with a single 
exception, full genome sequence was only obtained with at least 
80 days elapsing between the 2 infections (Figure 4C).
The analysis was expanded to include viral load data for 
3 human coronaviruses (HCoV-NL63, HCoV-229E, and 
HCoV-OC43) for all positive samples in the household cohort. 
When plotted by sample date, 3 patterns were observed. Type 
1 pattern: If the total amount of time a subject showed coro-
navirus-positive samples <14 days or if the subject had only a 
single coronavirus-positive sample the subject was considered 
to have a single infection. This group comprised the majority 
of subjects in the study (Table  2) and no conclusions about 
repeat infections could be made from this group. If there were 
at least 2 coronavirus-positive samples and the time between 
the first and last positive sample was ≥14 days and there were 
4 intervening NL6-negative samples, the subject was consid-
ered to have a repeat (type 2) infection. A type 2A pattern was 
defined as having any Ct values in the second half of the period 
higher than any Ct value in the first half of the period. A type 
2B pattern was defined as having any Ct values in the second 
half of the period lower than any Ct value in the first half of 
the period. Examples of individuals displaying the 2 patterns 
are shown in Supplementary Figure 2. The diagnostic results in 
Supplementary Figure  2A  show individuals with low Ct val-
ues initial samples and elevated Ct values in the reinfection 
samples consistent with a protective effect of prior exposure to 
the virus. In contrast, the diagnostic results in Supplementary 
Figure 2B show the reverse pattern with at least 1 reinfection Ct 
value lower than any Ct value in the initial infection, indicating 
greater virus growth in the second infection. An analysis of the 
3 coronavirus infections monitored in the cohort (HCoV-NL63, 
HCoV-229E, and HCoV-OC43) was performed to document 
the frequencies of these infection patterns across the entire 
cohort. HCoV-NL63 showed 21%, HCoV-229E showed 5%, and 
HCoV-OC43 showed 4% type 2 infections (Table 2). Among the 
type 2 infections, type 2A pattern (repeat infection higher Ct) 
was the majority pattern. However, all 3 coronaviruses showed 
a subset of repeat infections with higher viral loads (reduced Ct 
values) in the second exposure to the virus (Table 2).
We examined additional epidemiological data for first/
second infections. All infections in the household study 
appeared to be mild (Table  1). Additional respiratory viruses 
in the Picornaviridae (6 patients), Adenoviridae (1 patient), 
Orthomyxoviridae (1 patient) families were detected; however, 
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Figure 3. Global context of the Kilifi human coronavirus NL63 (HCoV-NL63) strains and diversity in the households genomes. A, A partial spike-based maximum likelihood 
(ML) phylogenetic tree of the combined Kilifi and global strains. B, A full-genome–based ML phylogenetic tree of the combined Kilifi and global strains. C, Local and global 
temporal circulation pattern of the lineages within genotype A and B. The blue symbols represent global strains while the orange symbols represent Kilifi strains. The scale 
bar indicates 0.01 (A)  or 0.001 (B) nucleotide substitutions per site.
Downloaded from https://academic.oup.com/jid/article-abstract/217/11/1728/4948258
by University of Warwick user
on 17 July 2018
HCoV-NL63 Evolutionary Patterns • JID 2018:217 (1 June) • 1735
we detected no association of coinfection with severity of the 
second coronavirus infection.
Comparing Sequences From First to Second Infection
One possible mechanism for repeat infection is that the sec-
ond infection is with a genetically distinct virus that avoids 
immune responses generated by the first infection. We 
attempted to determine if such genotype switching occurred 
between first and second infections; however, the overall low 
viral load of the first infections made this challenging. Only 
a total of 9146 nucleotides of HCoV-NL63 sequence were 
assembled from the first infections, making it difficult to per-
form a comparative phylogenetic analysis across pairs. As an 
alternative approach we applied a more sensitive kmer method 
to directly genotype the HCoV-NL63 short reads from first 
and second infection to determine if the repeat infections 
involved a shift to an alternate HCoV-NL63 genotype. Training 
sets of all HCoV-NL63 sequences, HCoV-NL63 genotype 
A sequences, and HCoV-NL63 genotype B sequences (>1000 
nt) was retrieved from GenBank and combined with the gen-
otype A  or B local spike sequences or the genotype A  full 
genomes. All 30-nt kmer sequences that were present in 1 gen-
otype and not the second were identified (see Methods and 
Table 3) and these genotype-specific kmers were used to clas-
sify the coronavirus reads from all 50 samples. Each read from 
each sample was examined for the presence of genotype-spe-
cific kmers. If 20 such kmers or more were identified with the 
300-nt read, the read was classified as genotype A or B. Using 
this method, 259 reads were classified as HCoV-NL63 using a 
combined HCoV-NL63 kmer set, and 151 of the HCoV-NL63 
reads could be classified by genotype and all 151 were geno-
type A.  Second infections were all classified as genotype A, 
consistent with the phylogenetic analyses (see Figures 2 and 
3), supporting a conclusion that genotype switching between 
the first and second infection is not required for reinfection.
DISCUSSION
The HCoV-NL63 is globally ubiquitous and may have been 
endemic in humans for a substantial time [44]. We provide 
evidence of human coronavirus repeat infections in a com-
munity study and rule out a possible mechanism of genotype 
switching.
The prevalence of HCoV-NL63 in severe pneumonia hospital 
admissions of children aged less than 5  years in rural coastal 
Kenya was low (1.3%) and varied considerably by year, consist-
ent with reports of HCoV-NL63 prevalence of 0.1%–6% [45–50]. 
HCoV-NL63 infections were detected with peak activity in 
May–July, coinciding with the cooler months of the year in this 
location (Figure 1B).
Two HCoV-NL63 genotypes were observed in Kilifi during 
the study period with a further diversification into lineages with 
a temporal clustering. Genotype A was observed in the majority 
of sampled infections in 2010, 2011, and 2014, while genotype 
B predominated in 2013. Inclusion of global sequences also sup-
ported this segregation of the HCoV-NL63 spike sequences into 
2 genotypes with sublineages. Notably, the community study 
observed only genotype A strains (no genotype B) but it is also 
important to note that the study lasted only 6 months. Further 
studies will determine if particular genotypes contribute to 
more severe respiratory infections.
The Global/Kilifi spike phylogeny indicated the past circu-
lation of up to 6 HCoV-NL63 lineages. Although the num-
ber of sequences is still too small for robust conclusions, it 
appears that local virus clades persist for some time: geno-
type A1 (2011–2013), genotype A2 (2010–2014), genotype B1 
(2008–2013), and genotype B2 (2011–2013). In most cases, 
genomic or spike sequences from other parts of the world can 
be identified that were close to each Kilifi genotype. This pat-
tern is consistent with a long period of local persistence with 
limited evolution of the virus, and perhaps the lack of immune 
pressure to change.
The observation that infection enhancement can occur after 
prior exposure to the virus, with strongest enhancement occur-
ring >80  days after initial exposure (Figure  4C), is consistent 
with an immune response playing a role. The majority of the 
repeat infections showed a pattern of reduced virus replica-
tion after prior exposure, which is consistent with the vaccine 
principle. Also there are likely to be cases of repeat exposure 
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to the virus where the second infection is blocked and these, 
of course, would not be detected in our study. However, for all 
3 endemic human coronaviruses a subset of repeat infections 
showed enhanced virus replication in the second infection. 
Thus it appears that host responses to HCoV-NL63 infections 
vary and may be dependent on the time elapsed since previous 
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Figure 4. A, Amino acid changes in the spike S1 domain of the human coronavirus NL63 (HCoV-NL63) from all available Kilifi and global sequences. Amino acid sequences 
were aligned and ordered by date of sample collection (oldest at bottom, most recent at top of figure). Sequences were ordered by genotype A (dark blue bar on Y axis) or 
genotype B (light blue bar) and Kilifi sequences are indicated by the orange bar. Changes in the protein relative to the reference sequence (derived from the reference genome 
GenBank NC_005831) are indicated by colored bars; the identity of the final amino acid is indicated at the bottom of the figure. Features of the spike protein are indicated in 
the diagram at the top of the figure. B, Comparison of the threshold cycle (Ct) values of the first and second infection community samples that were selected for whole-genome 
sequencing, with median value (blue), interquartile range (grey box), and individual Ct values (orange circles). Samples numbers were 25 first infections, 25 second infections. 
The difference between the first and second infection Ct values is much greater than expected by chance (P value from an unpaired t test was .0188). C, The % of full genome 
obtained from each of the 25 second infections, plotted as a function of the length of time between the first infection sample and the second infection sample.
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infection (Figure 4C). In addition, we speculate that the host’s 
prior exposure to the virus, the host’s HLA type, the quantity of 
virus in inoculum, and the host’s health status may influence the 
outcome of the exposure. If indeed these viruses exploit the host 
immune response to enhance infection, this mechanism could 
account for the low evolutionary rate of these viruses. There 
would be a negative selection of amino acid changes in immune 
epitopes that would disrupt this enhancement.
This study had limitations. Firstly, HCoV-NL63 single infection 
samples failed to yield full spike region or full genome sequences, 
most likely related to the low virus titers. Nonetheless, we could 
generate sufficient signal using a kmer approach (Table  3) to 
conclude that genotype switching did not accompany reinfec-
tion. We do realize the limitations of the kmer approach to detect 
specific differences in the reinfecting virus, such as changes in 
immune epitopes that might accompany reinfection. Secondly, 
our understanding of the global migration of HCoV-NL63 was 
hampered by the small number of HCoV-NL63 sequences avail-
able in GenBank. The limited global HCoV-NL63 sequence data 
meant that we could not infer the origins of HCoV-NL63 strains 
circulating in Kilifi with any detail. Nonetheless, the global data 
combined with the new Kilifi data from this report revealed a 
surprising stability in HCoV-NL63 with genotypes detectable 
globally over 10–15  years of observation. Recent increases in 
virus sequence surveillance will benefit this field and will pro-
vide data for a more detailed understanding of HCoV-NL63 
genetic diversity and phylogeography.
In summary, this study described HCoV-NL63 infection 
patterns in rural coastal Kenya. Two HCoV-NL63 genotypes 
circulated in Kilifi and this mirrored findings from global data. 
Virus lineages circulated within the community over several 
years, suggesting no requirement of reintroduction for per-
sistence and hence absence of herd immunity. Reinfections 
with HCoV-NL63 did not require genotype switching and 
there were multiple cases where the second infections resulted 
in higher viral loads than the initial infection, revealing inef-
fective protective immune responses after initial exposure to 
the virus. Finally, the new HCoV-NL63 sequences generated 
here provide useful data for coronavirus surveillance, primer 
design, and other efforts to document the evolutionary pat-
terns of this virus.
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aTotal number of quality-controlled short reads mapping to any HCoV-NL63 sequence (see 
Methods section).
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